knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 00:59:48 - browse：14946

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Hubble vs. James Webb telescope images: See the difference

hotspot

WSS

Russian special forces kill a gunman who broke into a private house near Moscow

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Skip the lead apron during X

UpToDate has a racism problem: Dr. Stanley Goldfarb

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

entertainment

knowledge

hotspot

Drug repurposing or repositioning? The language matters

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Supreme Court strikes down use of affirmative action

How artificial intelligence is being used to detect, treat cancer

Hepatitis C has a cure — but many Americans still lack access to it

How artificial intelligence is being used to detect, treat cancer

Jerome Adams on the need for new antivirals for Covid

What to know about Saharan dust affecting the US and how it can affect health

Jerome Adams on the need for new antivirals for Covid

'Screen and refer' systems are hurting patients

explore

FDA official pushes for dedicated emerging pathogens team

STAT wants to know your pick for a great summer read or listen

A double vaccine crisis is endangering millions of children

Crowdfunding for unproven stem cell procedures spreads misinformation

How artificial intelligence is being used to detect, treat cancer

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

hotspot

focus

focus

explore